Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Owkin

Biotech & Life Sciences · Paris, France · Founded 2016 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$1–2.5B
Latest valuation · Mar/2026
Unlock exact value
Revenue
$10–50M
Latest reported FY
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value

Collaborative research platform and unique AI drug development solutions that make precision medicine a reality

Investors

28 investors on Owkin's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
NJF Capital
Nicole Junkermann
Jean-Paul Clozel
Shana Fisher
Series A 10 investors entered at this stage
Series B+ 14 investors entered at this stage
Sanofi
École normale supérieure – PSL University
Alpha Intelligence Capital
INRIA
OTB Ventures
French National Centre for Scientific Research - CNRS
Serena
Google for Startups Accelerator
Bristol-Myers Squibb
SISTAFUND
CNRS Innovation
EIT Health
Karista
PSL University

Global footprint

Where Owkin has talent and traffic

AI talent share
21.4% of workforce is AI talent
(87 of 407 staff)
Core AI4912.04%
Other AI389.34%
Non-AI workforce32078.62%
Workforce by country
15 countries with
team presence
🇫🇷 France77.1%
🇬🇧 United Kingdom10.1%
🇺🇸 United States6.3%
🇩🇪 Germany2%
🇧🇪 Belgium0.7%
Top 5 of 15 shown
Web traffic by country
54K monthly visits
across markets
🇺🇸 United States17%
🇫🇷 France13.9%
🇬🇧 United Kingdom7.2%
🇦🇺 Australia6.1%
🏳️ Korea5.4%
Top 5 markets shown

Patent intelligence

$2M patent portfolio · 9 active families

Estimated portfolio value
$2M
0.23% of valuation · 336.5× smaller than top peer BioNTech ($780M)
9 active patent families
Where Owkin innovates Data miningMachine learningLearning modelsFeature vectorConvolutional neural network

Where Owkin concentrates vs peers

Each axis is a top-10 topic across Owkin and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Owkin's 3 investments and acquisitions.

Every disclosed deal where Owkin appeared as a backer or acquirer, 2023–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Owkin's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Owkin deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Owkin's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Sentiment on X

        What X is saying about Owkin

        An AI-synthesized read of the highest-engagement posts about Owkin on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Owkin on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.